PLoS ONE (Jan 2015)

Baicalein inhibits progression of gallbladder cancer cells by downregulating ZFX.

  • Tian-Yu Liu,
  • Wei Gong,
  • Zhu-Jun Tan,
  • Wei Lu,
  • Xiang-Song Wu,
  • Hao Weng,
  • Qian Ding,
  • Yi-Jun Shu,
  • Run-Fa Bao,
  • Yang Cao,
  • Xu-An Wang,
  • Fei Zhang,
  • Huai-Feng Li,
  • Shan-Shan Xiang,
  • Lin Jiang,
  • Yun-Ping Hu,
  • Jia-Sheng Mu,
  • Mao-Lan Li,
  • Wen-Guang Wu,
  • Bai-Yong Shen,
  • Li-Xin Jiang,
  • Ying-Bin Liu

DOI
https://doi.org/10.1371/journal.pone.0114851
Journal volume & issue
Vol. 10, no. 1
p. e0114851

Abstract

Read online

Baicalein, a widely used Chinese herbal medicine, has multiple pharmacological activities. However, the precise mechanisms of the anti-proliferation and anti-metastatic effects of baicalein on gallbladder cancer (GBC) remain poorly understood. Therefore, the aim of this study was to assess the anti-proliferation and anti-metastatic effects of baicalein and the related mechanism(s) on GBC. In the present study, we found that treatment with baicalein induced a significant inhibitory effect on proliferation and promoted apoptosis in GBC-SD and SGC996 cells, two widely used gallbladder cancer cell lines. Additionally, treatment with baicalein inhibited the metastasis of GBC cells. Moreover, we demonstrated for the first time that baicalein inhibited GBC cell growth and metastasis via down-regulation of the expression level of Zinc finger protein X-linked (ZFX). In conclusion, our studies suggest that baicalein may be a potential phytochemical flavonoid for therapeutics of GBC and ZFX may serve as a molecular marker or predictive target for GBC.